Monique E. van Leerdam

19.6k total citations · 2 hit papers
331 papers, 9.5k citations indexed

About

Monique E. van Leerdam is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Monique E. van Leerdam has authored 331 papers receiving a total of 9.5k indexed citations (citations by other indexed papers that have themselves been cited), including 245 papers in Oncology, 127 papers in Pathology and Forensic Medicine and 125 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Monique E. van Leerdam's work include Colorectal Cancer Screening and Detection (184 papers), Genetic factors in colorectal cancer (126 papers) and Gastric Cancer Management and Outcomes (115 papers). Monique E. van Leerdam is often cited by papers focused on Colorectal Cancer Screening and Detection (184 papers), Genetic factors in colorectal cancer (126 papers) and Gastric Cancer Management and Outcomes (115 papers). Monique E. van Leerdam collaborates with scholars based in Netherlands, United States and United Kingdom. Monique E. van Leerdam's co-authors include Ernst J. Kuipers, Evelien Dekker, Marjolein van Ballegooijen, Ewout W. Steyerberg, Lieke Hol, Anja Wagner, Paul Fockens, J. Dik F. Habbema, Anneke J. van Vuuren and Margot G F van Lier and has published in prestigious journals such as Nature, Nature Medicine and Nature Communications.

In The Last Decade

Monique E. van Leerdam

310 papers receiving 9.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study

2022 129 citations Monique E. van Leerdam et al. profile →
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial

2024 40 citations Marnix H. Geukes Foppen, Wieke H.M. Verbeek et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Monique E. van Leerdam Netherlands	52	6.5k	3.7k	3.5k	3.1k	987	331	9.5k
Tonya Kaltenbach United States	48	7.1k 1.1×	6.0k 1.6×	2.2k 0.6×	3.3k 1.1×	1.4k 1.5×	244	9.8k
Michael Bretthauer Norway	48	5.6k 0.8×	4.0k 1.1×	1.5k 0.4×	2.4k 0.8×	753 0.8×	214	8.0k
Janice N. Cormier United States	67	8.9k 1.4×	4.0k 1.1×	1.7k 0.5×	3.5k 1.2×	565 0.6×	242	13.5k
Iris Lansdorp‐Vogelaar Netherlands	49	9.8k 1.5×	5.9k 1.6×	3.5k 1.0×	2.9k 0.9×	302 0.3×	249	11.7k
John H. Donohue United States	56	4.1k 0.6×	3.9k 1.1×	1.2k 0.3×	5.0k 1.6×	1.2k 1.3×	155	9.2k
Anne‐Marie Bouvier France	46	4.5k 0.7×	1.9k 0.5×	1.6k 0.4×	2.5k 0.8×	430 0.4×	203	8.8k
Isabelle Ray‐Coquard France	64	7.0k 1.1×	5.5k 1.5×	1.9k 0.5×	3.6k 1.2×	2.3k 2.4×	418	16.7k
James E. East United Kingdom	46	4.4k 0.7×	3.4k 0.9×	1.2k 0.3×	2.6k 0.9×	927 0.9×	177	7.1k
Samir Gupta United States	45	4.2k 0.6×	2.7k 0.7×	1.3k 0.4×	1.8k 0.6×	264 0.3×	202	6.6k
Marinela Capanu United States	50	5.0k 0.8×	2.9k 0.8×	1.1k 0.3×	2.7k 0.9×	469 0.5×	249	9.1k

Countries citing papers authored by Monique E. van Leerdam

Since Specialization

Citations

This map shows the geographic impact of Monique E. van Leerdam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Monique E. van Leerdam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Monique E. van Leerdam more than expected).

Fields of papers citing papers by Monique E. van Leerdam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Monique E. van Leerdam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Monique E. van Leerdam. The network helps show where Monique E. van Leerdam may publish in the future.

Co-authorship network of co-authors of Monique E. van Leerdam

This figure shows the co-authorship network connecting the top 25 collaborators of Monique E. van Leerdam. A scholar is included among the top collaborators of Monique E. van Leerdam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Monique E. van Leerdam. Monique E. van Leerdam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Back, Tim R. de, Felice N. van Erning, Monique E. van Leerdam, et al.. (2025). Predisposing conditions in patients with small intestinal adenocarcinomas in the Netherlands: A 20‐year nationwide cohort study. International Journal of Cancer. 157(2). 218–231. 1 indexed citations

Acedo, Pilar, et al.. (2025). Recommendations, evidence and sustainability of screening for pancreatic cancer in high-risk individuals. Best Practice & Research Clinical Gastroenterology. 74. 101974–101974.

Leerdam, Monique E. van, et al.. (2024). Emerge of colorectal cancer in Lynch syndrome despite colonoscopy surveillance: A challenge of hide and seek. Critical Reviews in Oncology/Hematology. 197. 104331–104331. 2 indexed citations

Hooft, Jeanin E. van, Bas Boekestijn, Bert A. Bonsing, et al.. (2024). Aspects and outcomes of surveillance for individuals at high-risk of pancreatic cancer. Familial Cancer. 23(3). 323–339. 5 indexed citations

Brown, Sarah, et al.. (2024). Sarcopenia and Neuroendocrine Neoplasms. Current Oncology Reports. 26(2). 121–128. 3 indexed citations

Boot, Arnoud, Quinten R. Ducarmon, Sam Nooij, et al.. (2024). Enrichment of colibactin-associated mutational signatures in unexplained colorectal polyposis patients. BMC Cancer. 24(1). 104–104. 5 indexed citations

Pellisé, María, Barbara A.J. Bastiaansen, Monique E. van Leerdam, et al.. (2024). Risk of Cancer and Reoperation After Ileorectal Anastomosis and Ileal Pouch-Anal Anastomosis in Familial Adenomatous Polyposis. The American Journal of Gastroenterology. 120(9). 2132–2138. 2 indexed citations

Leerdam, Monique E. van, Margot Tesselaar, Parthi Srinivasan, et al.. (2024). High Prevalence of Sarcopenia in Patients with Newly Diagnosed Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs), but No Association with the Risk of Surgical Complications. Nutrients. 16(22). 3790–3790. 1 indexed citations

Ramsoekh, Dewkoemar, Emma Daulton, Sofie Bosch, et al.. (2024). Faecal Volatile Organic Compounds to Detect Colorectal Neoplasia in Lynch Syndrome—A Prospective Longitudinal Multicentre Study. Alimentary Pharmacology & Therapeutics. 61(1). 145–158. 2 indexed citations

10.

Wit, Meike de, Anne S. Bolijn, Marianne Tijssen, et al.. (2024). Polyketide synthase positive Escherichia coli one‐time measurement in stool is not informative of colorectal cancer risk in a screening setting. The Journal of Pathology. 263(2). 217–225.

11.

Jonge, Lucie de, Esther Toes‐Zoutendijk, Manon C.W. Spaander, et al.. (2023). Colorectal Cancer Stage Distribution at First and Repeat Fecal Immunochemical Test Screening. Clinical Gastroenterology and Hepatology. 21(13). 3424–3432.e2.

12.

Jodal, Henriette C., Pien M. Delis‐van Diemen, Dagmar Klotz, et al.. (2023). Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study. Cancer Research Communications. 3(11). 2292–2301.

13.

Gini, Andrea, Manon C.W. Spaander, Leon M.G. Moons, et al.. (2022). Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy. Cancer Epidemiology Biomarkers & Prevention. 31(12). 2157–2168. 3 indexed citations

14.

Carvalho, Beatriz, Tom van Wezel, Gerrit A. Meijer, et al.. (2022). Somatic hits in mismatch repair genes in colorectal cancer among non-seminoma testicular cancer survivors. British Journal of Cancer. 127(11). 1991–1996. 2 indexed citations

15.

Foppen, Marnix H. Geukes, Elisa A. Rozeman, Sandra van Wilpe, et al.. (2018). Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open. 3(1). e000278–e000278. 199 indexed citations

16.

Meulen, Miriam P. van der, Monique E. van Leerdam, Ernst J. Kuipers, et al.. (2017). Do Men and Women Need to Be Screened Differently with Fecal Immunochemical Testing? A Cost-Effectiveness Analysis. Cancer Epidemiology Biomarkers & Prevention. 26(8). 1328–1336. 17 indexed citations

17.

Snæbjörnsson, Pétur, Efraim H. Rosenberg, Peggy N. Atmodimedjo, et al.. (2016). Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment. Gut. 67(3). 447–455. 27 indexed citations

18.

Stegeman, Inge, Thomas R. de Wijkerslooth, Esther M. Stoop, et al.. (2013). Combining risk factors with faecal immunochemical test outcome for selecting CRC screenees for colonoscopy. Gut. 63(3). 466–471. 79 indexed citations

19.

Wijkerslooth, Thomas R. de, Esther M. Stoop, Patrick M. Bossuyt, et al.. (2011). Adenoma detection with cap-assisted colonoscopy versus regular colonoscopy: a randomised controlled trial. Gut. 61(10). 1426–1434. 82 indexed citations

20.

Cardoso, Joana, Renée X. de Menezes, Monique E. van Leerdam, et al.. (2006). Chromosomal Instability in MYH - and APC -Mutant Adenomatous Polyps. Cancer Research. 66(5). 2514–2519. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact